Ms Harrison has previously held the position of CFO for the company and takes over for Jonathan Green, CG Therapeutics’s first CEO, in an effort to move the company forward in new directions.
Prior to becoming CFO at CG Therapeutics, Ms Harrison was CFO and director of finance and human resources for Illumigen Biosciences from 2000 to 2007.
CG Therapeutics has also appointed two new board members, Reiner Laus and Julie Eastland. Dr Laus is founding CEO and president of BN Immunotherapeutics, a member of the Bavarian Nordic group. Ms Eastland is vice president of finance administration and CFO for Viral Logic Systems Technology.
Additionally, CG Therapeutics has recently concluded a licensing agreement to commercialize a patented platform technology that makes vaccines more potent by incorporating them in a slow-release formulation.